We are advocating targeted reimbursement of semaglutide 2.4 mg (Wegovy®) for secondary cardiovascular prevention in patients with established cardiovascular disease who are overweight or obese.
Reimbursement of semaglutide
16 July 2026
by
Belgian Society of Cardiology
in Advocacy